STAT3 and cancer: In blood cancer, they usually fulfill cancer driver roles when hyperactivated or when their expression is enhanced, where they can also function redundantly as oncoproteins requiring dual STAT3/5 targeting modes, as for the first time explored here with direct covalent STAT3/5 degraders.